In a post-market CV outcome study (the CARES trial),
1 a higher rate of CV fatal outcomes has been reported in patients with gout and established cardiovascular disease treated with ULORIC, when compared to those treated with allopurinol (see Background section for more details). In order to mitigate the risk identified in the CARES trial,
1 the ULORIC CPM has been updated to include the revised indication for use and additional safety information.
Products affected
ULORIC (febuxostat), 80 mg tablet (DIN 02357380)
Background information
Previously, ULORIC was indicated to lower serum uric acid levels in patients with gout (a first-line therapy). Based on the results of the CARES study,
1 ULORIC is now indicated to lower serum uric acid levels in patients with gout who have an inadequate response or intolerance to allopurinol, or for whom treatment with allopurinol is inappropriate (a second-line therapy).
The ULORIC indication was revised to enhance the safe use of ULORIC based on evidence identified in a recently completed, randomized, double-blind, allopurinol-controlled CARES study.
1 This study was conducted to evaluate the CV risk of ULORIC in patients with gout who had a history of major CV disease, cerebrovascular disease, or diabetes mellitus with micro- and/or macrovascular disease. The study compared the risk of major adverse CV events between patients treated with ULORIC (N=3098) and allopurinol-treated patients (N=3092). There was a higher rate of CV death in patients treated with ULORIC (134 CV deaths of 3098) compared to patients treated with allopurinol (100 CV deaths of 3092). All-cause mortality was higher in the ULORIC group (243 deaths of 3098) than the allopurinol group (199 deaths of 3092) due to a higher rate of CV deaths (see Table 1 for details). Sudden cardiac death was the most common cause of adjudicated CV deaths in the ULORIC group (83 of 3098; 2.7%) as compared to the allopurinol group (56 of 3092; 1.8%).
Table 1: Patients with MACE* in CARES (Cardiovascular Outcomes Study in Patients with Gout) 1
|
|
ULORIC
N=3098 |
Allopurinol
N=3092 |
Hazard Ratio |
|
|
Number of Patients with Event (%) |
Rate per 100 PY** |
Number of Patients with Event (%) |
Rate per 100 PY** |
95% CI |
|
Cardiovascular Death |
134 (4.3%) |
1.5 |
100 (3.2%) |
1.1 |
1.34
(1.03, 1.73) |
|
All-cause mortality |
243 (7.8%) |
2.6 |
199 (6.4%) |
2.2 |
1.22
(1.01, 1.47) |
*Major adverse cardiovascular events (MACE)
**Patient Years (PY)
Further to narrowing the ULORIC indication for use, additional changes were made to the ULORIC CPM to further mitigate the risk identified in the CARES study.
1 The increased risk of CV fatal outcomes has been included in the
Serious Warnings and Precautions Box of the ULORIC CPM. The
Warnings and Precautions, Adverse Reactions, Clinical Trials and Consumer Information sections in the CPM have also been updated in relation to this issue.